Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 511 to 525 of 669 results for kidney or kidneys or renal

  1. Phosphate binders: Which binders are the most clinically and cost effective in controlling serum phosphate in adults, children and young people with stage 4 or 5 CKD who are not on dialysis?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  2. Investigations for proteinuria: What is the effect of measuring proteinuria with albumin:creatinine ratio compared with protein:creatinine ratio on the timing of treatment changes in children and young people with CKD? [2021]

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  3. Managing anaemia: For adults, children and young people with CKD and anaemia, what is the diagnostic accuracy of eGFR thresholds of 60, 45, and 30 ml/min/1.73 m2 for determining whether the anaemia is due to CKD?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  4. Managing anaemia: For adults, children and young people with CKD and anaemia who are on peritoneal dialysis, what amount of intravenous (IV) iron is most clinically and cost effective in managing anaemia and its associated outcomes (including quality of life)?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  5. Management of anaemia of CKD with concurrent illness: What is the optimal management (in terms of clinical and cost effectiveness) of anaemia of CKD in people who are receiving erythropoietic stimulating agents (ESAs) and have a significant concurrent acute infectious illness?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  6. Phosphate binders: In adults with stage 4 or 5 CKD, including those on dialysis, what is the clinical and cost effectiveness and safety of long-term calcium acetate combined with magnesium carbonate for controlling serum phosphate?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  7. Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)

    This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    5 December 2018
    View recommendations

    Sections for NG114

  8. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (IPG754)

    We have moved interventional procedures guidance 754 to become HealthTech guidance 662. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Laparoscopic renal denervation for loin pain haematuria syndrome (IPG709)

    We have moved interventional procedures guidance 709 to become HealthTech guidance 596. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  10. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    Discontinued Reference number: GID-TA11086

    Technology appraisal guidance
    Discontinued

  11. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA158

  12. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

    Technology appraisal guidance
    Published
    25 February 2009
    View recommendations

    Sections for TA168

  13. Acute upper gastrointestinal bleeding in adults (QS38)

    This quality standard covers the management of acute upper gastrointestinal bleeding in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    30 July 2013
    View quality statements

    Sections for QS38

  14. HIV testing: encouraging uptake (QS157)

    This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    7 September 2017
    View quality statements

    Sections for QS157

  15. Hyperphosphatemia in people with CKD stage 4 or 5: What are people with CKD and their family members and carers views and beliefs about taking oral phosphate binders?

    binders. Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021